ProVise Management Group LLC increased its holdings in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 11.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,275 shares of the company’s stock after acquiring an additional 3,094 shares during the quarter. ProVise Management Group LLC’s holdings in Elevance Health were worth $11,383,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in ELV. BlackRock Inc. bought a new position in Elevance Health during the second quarter worth $7,344,424,000. State Street Corp increased its holdings in shares of Elevance Health by 1.3% in the second quarter. State Street Corp now owns 10,426,610 shares of the company’s stock valued at $4,032,283,000 after purchasing an additional 137,914 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Elevance Health by 12.0% in the second quarter. Wellington Management Group LLP now owns 9,213,513 shares of the company’s stock valued at $3,563,142,000 after purchasing an additional 984,976 shares during the period. First Eagle Investment Management LLC raised its position in shares of Elevance Health by 1.4% in the second quarter. First Eagle Investment Management LLC now owns 4,188,196 shares of the company’s stock valued at $1,619,701,000 after purchasing an additional 55,905 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in shares of Elevance Health in the second quarter valued at about $1,246,349,000. Institutional investors own 89.24% of the company’s stock.
Wall Street Analyst Weigh In
Several analysts recently commented on ELV shares. Wall Street Zen raised shares of Elevance Health from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Royal Bank Of Canada upped their price target on shares of Elevance Health from $424.00 to $455.00 and gave the company a “sector perform” rating in a research note on Thursday, October 22nd. Robert W. Baird increased their price target on shares of Elevance Health from $393.00 to $406.00 and gave the company a “neutral” rating in a report on Thursday, October 22nd. TD Cowen raised their price objective on shares of Elevance Health from $465.00 to $495.00 and gave the stock a “buy” rating in a research report on Friday, October 23rd. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $451.00 price objective on shares of Elevance Health in a report on Friday, October 23rd. Fifteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $456.48.
Elevance Health Stock Performance
Shares of Elevance Health stock opened at $429.50 on Monday. The company has a 50 day moving average of $415.40 and a 200-day moving average of $375.20. Elevance Health, Inc. has a 1-year low of $274.84 and a 1-year high of $450.69. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 0.68. The company has a market cap of $92.80 billion, a PE ratio of 18.32, a price-to-earnings-growth ratio of 2.05 and a beta of 0.63.
Elevance Health (NYSE:ELV – Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.71 by $2.28. The business had revenue of $50.44 billion for the quarter, compared to analysts’ expectations of $49.28 billion. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The firm’s quarterly revenue was up .7% compared to the same quarter last year. During the same period last year, the firm posted $6.03 earnings per share. As a group, equities research analysts forecast that Elevance Health, Inc. will post 29.15 earnings per share for the current fiscal year.
Elevance Health Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be paid a dividend of $1.72 per share. The ex-dividend date is Friday, December 4th. This represents a $6.88 annualized dividend and a yield of 1.6%. Elevance Health’s dividend payout ratio is presently 29.34%.
Insiders Place Their Bets
In other news, CFO Mark Kaye sold 10,584 shares of the business’s stock in a transaction on Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the completion of the transaction, the chief financial officer owned 19,919 shares of the company’s stock, valued at approximately $8,766,949.47. The trade was a 34.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Ratnakar Lavu sold 1,300 shares of the business’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $440.00, for a total value of $572,000.00. Following the transaction, the executive vice president directly owned 14,849 shares of the company’s stock, valued at $6,533,560. This trade represents a 8.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.34% of the company’s stock.
About Elevance Health
Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.
Featured Articles
- Five stocks we like better than Elevance Health
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
